| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $8.97 | - | - |
| Q3'26 | $9.32 | $9.40 | +0.8% |
| Q3'25 | $8.62 | $8.81 | +2.2% |
| Q2'25 | $8.55 | $9.38 | +9.7% |
| Q1'25 | $8.08 | $8.41 | +4.0% |
| Q4'24 | $7.76 | $8.20 | +5.7% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $3.3B | - | - |
| Q3'26 | $3.4B | $3.4B | -0.6% |
| Q3'25 | - | $3.2B | - |
| Q2'25 | - | $3.2B | - |
| Q1'25 | - | $3.1B | - |
| Q4'24 | - | $3.1B | - |
Market Data
KLAC is currently trading at $212.30, giving KLA Corporation a market cap of 285.16B and a P/E ratio of 61.0. Today's range spans $206.22–$216.32, with shares opening at $210.99 and moving down $5.68 (2.6%) from the prior close. DailyIQ's technical score sits at 14/100 (SELL) with a news sentiment reading of 61/100.
Over the past year KLAC has traded between $83.22 and $307.37 - the current price is +155.1% off the 52-week low and -30.9% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $232.43 (range $150.00–$325.00), implying upside of +9.5%.
KLAC: large-cap, Technology, 285.16B market cap. (P/E: 61.0) Technical score 14/100 (SELL). Sentiment: bullish (61/100). Price: $212.30 (in the middle of its 52-week range). Range: $83.22–$307.37. The SELL designation at this capitalization tier doesn't mean the stock is uninvestable - it means the risk/reward of buying dips hasn't been restored yet, and patience or an outright hedge is often the better posture until technical conditions improve.
Analyst coverage for KLAC becomes a double-edged factor in a SELL phase: at 285.16B in Technology market cap, active coverage is high enough that downgrade risk is real and impactful. The 14/100 technical reading and bullish sentiment (61/100) at $212.30 (in the middle of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $83.22–$307.37 range establishes where that repricing lands.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).